Search Beyond News…

Alan raises €480 million Series G led by Prosus, boosting European health‑tech funding

Executive summary: Alan secured a €480 million Series G funding round led by Prosus. The deal signals strong investor confidence in European health‑tech and adds to record venture funding in the sector.

Who is involved: Alan (health‑tech unicorn), Prosus (lead investor), and existing backers (not named).

Likely next: Proceeds will fund product development, geographic expansion, and potential follow‑on M&A or IPO activity.

Alan, a European health‑tech unicorn, closed a Series G round totaling €480 million, with Prosus acting as lead investor. The round values the company at a multi‑billion‑euro level, though the exact valuation was not disclosed. The investment reflects continued appetite for digital health ventures despite broader market volatility. Prosus’s involvement may bring strategic synergies with its existing consumer‑internet portfolio.

What's next — scenarios

Strategic Ecosystem Integration (50%)

Increased market share in Europe via Prosus's existing digital platform synergies.

Scale-Driven Burn (30%)

High capital expenditure on user acquisition potentially delaying profitability.

Valuation Compression/Downround Risk (20%)

Downstream investors may demand stricter terms in Series H.

What to watch

Timeline

Analysis — what this means

Likely next events

Sectors affected

Regulatory implications

Historical parallels

Key entities

Sources

Browse the full archive →